Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Genomic Medicine, |
RCV000668784 | SCV001156407 | pathogenic | Bardet-Biedl syndrome 1 | 2019-02-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001377153 | SCV001574403 | likely pathogenic | Bardet-Biedl syndrome | 2024-12-04 | criteria provided, single submitter | clinical testing | This sequence change affects codon 370 of the BBS1 mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the BBS1 protein. This variant also falls at the last nucleotide of exon 11, which is part of the consensus splice site for this exon. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has been observed in individuals with BBS1-related conditions (PMID: 16877420, 23432027; internal data). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 553357). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
Gene |
RCV001756134 | SCV001986114 | likely pathogenic | not provided | 2022-12-06 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 16877420, 23432027, 22773737) |
Counsyl | RCV000668784 | SCV000793439 | uncertain significance | Bardet-Biedl syndrome 1 | 2017-08-16 | flagged submission | clinical testing | |
Prevention |
RCV004723052 | SCV005336911 | uncertain significance | BBS1-related disorder | 2024-03-14 | no assertion criteria provided | clinical testing | The BBS1 c.1110G>A variant is not predicted to result in an amino acid change (p.=). This variant occurs at the last nucleotide of exon 11 and is predicted to alter splicing based on available splicing prediction programs (SpliceAI, Jaganathan et al. 2019. PubMed ID: 30661751). However, the use of computer prediction programs is not equivalent to functional evidence. This variant has been reported in the homozygous state in at least one individual of Tunisian ancestry with Bardet-Biedl syndrome; however, no additional evidence was provided to support its pathogenicity (Table 2, Smaoui et al. 2006. PubMed ID: 16877420; Table 3, Redin et al. 2012. PubMed ID: 22773737; Table 2, M'hamdi et al. 2014. PubMed ID: 23432027). This variant is reported in 0.0050% of alleles in individuals of East Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |